A randomized phase II study of CHO(E)P vs CC-486-CHO(E)P vs duvelisib-CHO(E)P in previously untreated CD30 negative peripheral T-cell lymphomas
Study of Duvelisib or Azacitidine in Addition to Chemotherapy in Patients with Peripheral T-Cell Lymphoma (PTCL)
Sponsor: NIH
Enrolling: Male and Female Patients
IRB Number: AAAT9879
U.S. Govt. ID: NCT04803201
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to compare the usual treatment alone to using duvelisib or CC-486 plus the usual treatment for patients with peripheral T-cell lymphoma. The usual approach for patients who are not in a study is treatment with the FDA-approved chemotherapy regimens used in this trial (CHOP or CHOEP) without the addition of the study drugs duvelisib or CC-486 (azacitidine). The addition of duvelisib or CC-486 (azacitidine) to the usual treatment may or may not increase the chance of cancer going into remission. But, it could also cause side effects, which the study doctors want to monitor. This study will help the study doctors find out if this different approach is the same, worse, or better than the usual approach. To decide if it is better, the study doctors will be looking to see if the study drugs added to the usual approach increase the remission rate compared to the usual approach alone.
Jennifer Amengual, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with peripheral T-cell lymphoma (PTCL) that has not been previously treated? Yes No
Are you able to make regularly scheduled visits to the clinic for treatment and examinations? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator